Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | adenosine A2b receptor | Starlite/ChEMBL | References |
Homo sapiens | adenosine A1 receptor | Starlite/ChEMBL | References |
Homo sapiens | adenosine A3 receptor | Starlite/ChEMBL | References |
Homo sapiens | adenosine A2a receptor | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | follicle stimulating hormone receptor | adenosine A2a receptor | 412 aa | 336 aa | 22.3 % |
Brugia malayi | hypothetical protein | adenosine A1 receptor | 326 aa | 305 aa | 21.0 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Entamoeba histolytica | phosphoglycerate mutase family protein, putative | 0.1691 | 0.5485 | 0.5 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase 1 | 0.2817 | 0.9814 | 0.9706 |
Brugia malayi | brahma associated protein 60 kDa | 0.0264 | 0 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0264 | 0 | 0.5 |
Schistosoma mansoni | 6-phosphofructokinase | 0.2865 | 1 | 1 |
Echinococcus multilocularis | 6 phosphofructo 2 kinase:fructose 2 | 0.2865 | 1 | 1 |
Echinococcus granulosus | tumor protein p63 | 0.072 | 0.1752 | 0.1752 |
Plasmodium falciparum | SWIB/MDM2 domain-containing protein | 0.0264 | 0 | 0.5 |
Leishmania major | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.2865 | 1 | 1 |
Trypanosoma brucei | 6-phosphofructo-2-kinase 2 | 0.2817 | 0.9814 | 0.9706 |
Leishmania major | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.2817 | 0.9814 | 0.9706 |
Loa Loa (eye worm) | hypothetical protein | 0.2865 | 1 | 1 |
Mycobacterium ulcerans | fructose-2,6-bisphosphatase GpmB | 0.1691 | 0.5485 | 0.5 |
Plasmodium falciparum | SWIB/MDM2 domain-containing protein | 0.0264 | 0 | 0.5 |
Brugia malayi | brahma associated protein 60 kDa | 0.0264 | 0 | 0.5 |
Mycobacterium ulcerans | hypothetical protein | 0.1691 | 0.5485 | 0.5 |
Plasmodium vivax | hypothetical protein, conserved | 0.0264 | 0 | 0.5 |
Giardia lamblia | Hypothetical protein | 0.1691 | 0.5485 | 0.5 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.2865 | 1 | 1 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.2865 | 1 | 1 |
Toxoplasma gondii | SWIB/MDM2 domain-containing protein | 0.0264 | 0 | 0.5 |
Chlamydia trachomatis | DNA topoisomerase I | 0.0264 | 0 | 0.5 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase 1 | 0.2817 | 0.9814 | 0.9706 |
Chlamydia trachomatis | SWIB complex protein | 0.0264 | 0 | 0.5 |
Plasmodium vivax | SWIB/MDM2 domain-containing protein, putative | 0.0264 | 0 | 0.5 |
Brugia malayi | SWIB/MDM2 domain containing protein | 0.0264 | 0 | 0.5 |
Toxoplasma gondii | DNA topoisomerase domain-containing protein | 0.0264 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.2817 | 0.9814 | 0.9814 |
Loa Loa (eye worm) | hypothetical protein | 0.1643 | 0.53 | 0.53 |
Echinococcus multilocularis | tumor protein p63 | 0.072 | 0.1752 | 0.1752 |
Onchocerca volvulus | 0.2865 | 1 | 1 | |
Giardia lamblia | Hypothetical protein | 0.1691 | 0.5485 | 0.5 |
Trypanosoma brucei | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.2865 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Ki (binding) | = 676 nM | Displacement of [3H]HEMADO from human adenosine A3 receptor expressed in CHO cells | ChEMBL. | 23685887 |
Ki (binding) | = 4870 nM | Displacement of [3H]NECA from human adenosine A2A receptor expressed in CHO cells | ChEMBL. | 23685887 |
Ki (binding) | = 7240 nM | Displacement of [3H]CCPA from human adenosine A1 receptor expressed in CHO cells | ChEMBL. | 23685887 |
Ki (binding) | > 10000 nM | Antagonist activity at human adenosine A2B receptor expressed in CHO cells assessed as inhibition of NECA-stimulated adenylyl cyclase activity | ChEMBL. | 23685887 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.